Keywords: Orexigen, Contrave, Obesity, Blood pressure, ACC, Research

Orexigen soars after saying obesity drug Contrave does not impact blood pressure

Article | 05 April 2011

Orexigen Therapeutics (Nasdaq: OREX) saw its shares rocket 16.7% to $3.36 in morning trading yesterday, after announcing additional data showing that overweight ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Orexigen Therapeutics

Go to company listing

Related Drugs

Contrave

Go to drug listing